Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis


The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.

Full Title of Study: “Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2020


  • Drug: H.P. ACTHAR GEL
    • H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.

Arms, Groups and Cohorts

  • Experimental: H.P. ACTHAR GEL

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of responders to Acthar at the end of treatment.
    • Time Frame: 24 Weeks
    • A responder will be defined by the binominal presence or absence of active retinal vasculitis as evaluated at Week 24. Active retinal vasculitis is defined as angiographic leakage from retinal arterioles, venules, or capillaries as determined by investigator, seen on wide-field angiography. Complete resolution or absence of active retinal vasculitis at Week 24 is considered success or “remission”.

Secondary Measures

  • Presence or absence of active retinal vasculitis at all other time points.
    • Time Frame: 1 Day to 24 Weeks
  • Safety assessments, including drug tolerability and adverse events; other ocular and/or systemic complications.
    • Time Frame: 1 Day to 24 Weeks
  • Percentage of patients requiring rescue therapy.
    • Time Frame: 1 Day to 24 Weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Any adult patient with active retinal vasculitis (involving arteries or veins) as a manifestation of non-infectious ocular inflammatory disease; fundus must be viewable with wide-field FA in the study eye – If both eyes are involved, both are eligible for inclusion in the study – Patients already on non-steroidal immunosuppressive therapy may continue on this during the study, but the dose must not be increased or decreased within 6 weeks of initiating the trial – Willing and able to sign the informed consent form Exclusion Criteria:

  • Patients under age 18 – Patients who are pregnant (must be ruled out in women of child-bearing age) – Active infectious ocular or systemic disease – Patients with active infectious ocular or extraocular disease – Patients with history of malignancy, except for dermatologic entities of basal or squamous cell carcinoma which have been completely excised or removed previously – Patients with systemic illness involving abnormalities of the hypothalamic-pituitary-adrenal axis; patients with primary adrenocortical insufficiency or adrenocortical hyperfunction – Patients with known hypersensitivity to Acthar – Patients on other non-steroidal systemic immunomodulatory medications with dose adjusted sooner than 6 weeks prior to study drug administration – Patients currently on or recently treated with (within 6 weeks) systemic corticosteroid – Patients with periocular or intraocular injections of medications administered to help control inflammation sooner than 6 weeks prior to study drug administration – Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator, or contraindicated, including but not limited to, patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin. Administration of live or live attenuated vaccines is contraindicated in patients during the entire duration of the study and for one month prior

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ocular Immunology and Uveitis Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • C. Stephen Foster, MD, 781-891-6377, sfoster@mersi.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.